NAD+ Metabolism ·
SRN-901, a novel drug targeting NAD+ pathways, significantly extends lifespan and healthspan in aging mice. This research highlights the complexity of aging and the need for multifaceted interventions to address it. By combining various compounds, SRN-901 offers a promising approach to enhance health during aging.
What this study examined
This study investigated the effects of SRN-901, a novel oral combinatorial drug, on lifespan and healthspan in 18-month-old mice fed a Western diet. The drug contains urolithin A, quercetin, nicotinamide riboside, alpha-lipoic acid, and Seragon's SRN-820. The primary outcomes included median remaining lifespan, frailty reduction, and changes in gene expression related to aging.
Why this matters for longevity research
The findings from this study are significant as they address the interconnected nature of biological aging. Traditional geroprotective compounds often fail to produce substantial lifespan extensions due to their singular focus. SRN-901's multi-target approach provides insights into how combinations of compounds can synergistically enhance healthspan and lifespan, aligning with the emerging understanding of aging as a multifactorial process.
Key findings
- SRN-901 treatment resulted in a 33% increase in median remaining lifespan compared to placebo.
- Cox proportional hazards analysis indicated a 46% reduction in the hazard of death for treated mice.
- Treated mice showed a significant reduction in frailty progression, with scores indicating a 70% attenuation compared to controls.
- Transcriptomic analyses revealed modulation of gene expression across several aging-related pathways, including inflammation and DNA repair.
- Metabolic profiling indicated that SRN-901 improved the blood metabolite profile, making it resemble that of younger mice.
- Upregulation of glutathione metabolism was observed, enhancing cellular defenses against oxidative stress.
- SRN-901's effects suggest a potential for broader applications in addressing age-related diseases, including neurodegenerative disorders.
The science behind it
The role of NAD+ in aging is well-documented, particularly its involvement in sirtuin activation, which is crucial for cellular health and longevity. Sirtuins are a family of proteins that regulate various biological pathways, including metabolism and stress resistance. By enhancing NAD+ levels through compounds like nicotinamide riboside, researchers aim to improve mitochondrial function and promote longevity. SRN-901's combination of ingredients targets multiple pathways, including oxidative stress response and metabolic regulation, which are essential for maintaining health during aging.
How it fits into the longevity field
SRN-901 represents a shift towards combinatorial approaches in longevity research, similar to other interventions like rapamycin and NMN. While rapamycin has shown lifespan extension in animal models, the lack of significant effects from NMN and NR highlights the necessity for multi-target strategies. This study positions SRN-901 within a growing body of literature advocating for comprehensive interventions to combat the multifaceted nature of aging.
Practical takeaways
Researchers and informed consumers should consider the implications of SRN-901's findings for future longevity studies. The results underscore the importance of targeting multiple aging pathways rather than relying on single compounds. Understanding the mechanisms through which SRN-901 operates can inform the development of new interventions aimed at enhancing healthspan and lifespan. Further research is needed to explore the long-term effects and potential applications of SRN-901 in human aging.
FAQ
What is SRN-901?
SRN-901 is a novel oral drug that combines multiple compounds, including NAD+ precursors, to target various aging pathways.
How does SRN-901 affect lifespan?
In studies, SRN-901 has been shown to extend median lifespan by 33% in aging mice compared to placebo.
What are the implications of this research?
This research highlights the potential for multi-target approaches in longevity, suggesting that combinations of compounds may be more effective than single interventions.
Source: PubMed · Drug Des Devel Ther · published 2026-01-01.